Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.


Options:
A: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Dasatinib + Placebo | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib plus Dasatinib | Arm Label: Arm D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Dasatinib + Placebo; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Erlotinib plus Dasatinib; Assigned to Arm(s): Arm C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm D | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm A
C: Arm Label: postop chemoradio with cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Radiation: chemoradiotherapy with cisplatin | Arm Label: postop chemoradio (cisplatin)+gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Iressa (Gefitinib) | Intervention Type: DRUG; Name: Iressa (Gefitinib); Assigned to Arm(s): postop chemoradio (cisplatin)+gefitinib | Intervention Type: RADIATION; Name: chemoradiotherapy with cisplatin; Assigned to Arm(s): postop chemoradio with cisplatin
D: Arm Label: Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer); Type: EXPERIMENTAL; Interventions: Drug: erlotinib hydrochloride, Drug: cisplatin, Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy, Procedure: quality-of-life assessment | Arm Label: Arm II (chemotherapy, radiotherapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin, Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy, Procedure: quality-of-life assessment | Intervention Type: DRUG; Name: erlotinib hydrochloride; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: RADIATION; Name: 3-dimensional conformal radiation therapy; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy) | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer), Arm II (chemotherapy, radiotherapy)

Answer: A